Jazz Pharmaceuticals (JAZZ) Change in Account Payables (2010 - 2026)

Jazz Pharmaceuticals' Change in Account Payables history runs 17 years deep, the most recent figure standing at -$21.4 million for Q1 2026.

• In Q1 2026, Change in Account Payables fell 212.04% year-over-year to -$21.4 million; the TTM figure through Mar 2026 stood at -$649000.0 (down 103.48% YoY), while the FY2025 annual figure was $39.9 million, up 298.53% from the prior year.
• Change in Account Payables for Q1 2026 stood at -$21.4 million, up from -$29.0 million in the prior quarter.
• The five-year high for Change in Account Payables was $62.4 million in Q3 2025, with the low at -$29.0 million in Q4 2025.
• The 5-year median for Change in Account Payables is -$8.1 million (2023), against an average of -$190823.5.
• The sharpest annual moves came in 2022 and 2023: Change in Account Payables surged 20493.66% in 2022, then slumped 1042.52% in 2023.
• Jazz Pharmaceuticals' Change in Account Payables stood at -$15.4 million in 2022, then jumped by 47.43% to -$8.1 million in 2023, then soared by 61.31% to -$3.1 million in 2024, then slumped by 824.15% to -$29.0 million in 2025, then increased by 26.14% to -$21.4 million in 2026.
• Business Quant data shows JAZZ's Change in Account Payables at -$21.4 million in Q1 2026, -$29.0 million in Q4 2025, and $62.4 million in Q3 2025.